Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Félix Gutiérrez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Pyridones, Anti-HIV Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU.
Abstract (Originalsprache)
Background
This study aimed to investigate factors contributing to non-sustained viral suppression, including intermittent viremia and persistent low-level viremia, during cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) injectable therapy, with a focus on pharmacokinetics (PK).
Methods
A prospective cohort study was conducted on people with human immunodeficiency virus (HIV, PWH) transitioning from stable oral antiretroviral therapy (ART) to bimonthly CAB + RPV LA. Standardized follow-up included close monitoring through blood sampling for plasma human immunodeficiency virus type 1 (HIV-1) viral load (VL) and multiple plasma drug concentrations measurements to analyze the connection between PK parameters and virologic outcomes.
Results
Among 173 patients with a median (interquartile range [IQR]) follow-up of 11.1(7.1–13.2) months and 789 pre-dose measurements, 38.7% experienced VL ≥ 20 copies/mL, and 16.2% had levels ≥50 copies/mL. Intermittent viremia occurred in 34.7% of patients, and persistent low-level viremia in 4%. Virological failure developed in 2 cases. Predictors of non-sustained viral suppression included VL at HIV diagnosis (adjusted hazard ratio [AHR]: 1.49 per log10 VL, 95% confidence interval [CI]: 1.04–2.12, P = .027), detectable viremia on oral ART (AHR: 2.45, 95% CI: 1.29–4.65, P = .006), and the level of viral suppression at transition (AHR: 0.38, 95% CI: .19–.75, P = .004). We found a significant association between low trough concentrations of CAB and RPV and episodes of detectable viremia exceeding 50 copies/mL. However, none of the assessed PK covariates predicted non-sustained viral suppression in multivariable models.
Conclusions
Non-sustained viral suppression in PWH transitioning from stable oral ART to CAB + RPV LA was linked to preexisting factors before transition. Higher VL pre-ART and incomplete suppression on oral therapy increased the risk, independent of PK parameters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain.
- Department of Clinical Medicine, Universidad Miguel Hernández, Alicante, Spain.
- CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
- Institute for Research, Development and Innovation in Health Biotechnology of Elche (IDiBE), Universidad Miguel Hernández, Elche, Spain.
ORCID-Profile: Félix Gutiérrez, Marta Fernández-González, Christian Ledesma, María Losada-Echeberría, Enrique Barrajón-Catalán, Javier García-Abellán, Leandro López, Melissa Bello-Perez, Sergio Padilla, Mar Masiá
Förderung
- Consorcio Centro de Investigación Biomédica en Red
- Instituto de Salud Carlos III
- Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU
- Sara Borrell program
- Instituto de Salud Carlos III and MLE
- Ministerio de Universidades, Spain
- Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU
Zitieren
APA
Gutiérrez, F., Fernández-González, M., Ledesma, C., Losada-Echeberría, M., Barrajón-Catalán, E., García-Abellán, J., De Stefano, D., López, L., Bello-Perez, M., Padilla, S., & Masiá, M. (2025). Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae475
Vancouver
Gutiérrez F, Fernández-González M, Ledesma C, Losada-Echeberría M, Barrajón-Catalán E, García-Abellán J, et al. Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae475
BibTeX
@article{Gutirrez2025,
author = {Gutiérrez, Félix and Fernández-González, Marta and Ledesma, Christian and Losada-Echeberría, María and Barrajón-Catalán, Enrique and García-Abellán, Javier and De Stefano, Daria and López, Leandro and Bello-Perez, Melissa and Padilla, Sergio and Masiá, Mar},
title = {Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae475}
}
EUVIMED